A Phase 1 interventional study of Artesunate (Test) and Artesunate (Comparator) in Falciparum Malaria, sponsored by Pfizer. Completed at 1 site in Singapore. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-06-25.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing artesunate in Malaria, Falciparum — none open to participants now, none under way, none of them phase 3. Artesunate · Malaria, Falciparum.
Among the 25 studies testing artesunate in Malaria, Falciparum, this one is the 21st largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2009, is the only one in phase 1, and was the 14th registered.
456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.
Browse Malaria, Falciparum studies →None of the 25 studies testing artesunate in Malaria, Falciparum is open now. The open studies under Malaria, Falciparum, anywhere →
Artesunate: first FDA approval 2020 (ARTESUNATE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 22 Malaria, Falciparum studies recruiting now, 6 (27%) set no upper age limit and 15 (68%) stop at 75 or younger; 14 take children under 18; 9 take healthy volunteers.
This study: 21 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 6 · Phase 4 8
First in 2000; this study’s year is marked. 1 started in 2009.
This study's enrollment of 40 is below the median of 126 across 376 interventional studies indexed under Malaria, Falciparum.
Median enrollment 228 across the 23 interventional studies. Of the 23 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 25 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
10 studies in Malaria, Falciparum by Pfizer: none open now, none under way, none of them phase 3. Of 10 finished, 2 (20%) have results posted.
Among the 10 studies in Malaria, Falciparum by Pfizer, this one is the 6th largest by enrollment, is one of 3 that started in 2009, is one of 2 in phase 1, and was the 9th registered.
Pfizer’s Malaria, Falciparum studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing artesunate in Malaria, Falciparum, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 10 in Malaria, Falciparum:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will determine if artesunate tablet (Pfizer), an antimalarial agent, is pharmaceutically equivalent to Arsuamoon® tablets (Guilin-China).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Artesunate (Test)
Drug: Artesunate (Comparator)
Oral tablet, single dose, 1 x 100 mg
Oral tablet, single dose, 2 x 50 mg
AUC and Cmax of active metabolite of artesunate
Time frame: 30-Aug-2009
Tolerability
Time frame: 30-Aug-2009
The record gives a start of Jun 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Artesunate